Skip to main content
Premium Trial:

Request an Annual Quote

ATCC, BioMerieux Collaborate to Expand Microbial Database

NEW YORK (GenomeWeb) – ATCC and BioMérieux today said they are collaborating to expand the BioMérieux Vitek MS microbial identification database for the industrial market.

ATCC, based in Manassas, Va., recently acquired the MALDI-TOF instrument and is integrating it into its quality development process to enable it to generate a large pathogen knowledgebase that will then be incorporated into the Vitek MS database. The expanded database will improve the accuracy and range of microbial identification of the BioMérieux technology and improve its utility for customers, the companies said.

"The solution will also provide traceability and reduced testing time while reducing consumable costs in our extensive quality control process," Kristina Peterman, senior director of compliance and regulatory affairs, and chief compliance officer of ATCC, said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.